New cloud-based platform is being developed to integrate artificial intelligence, automated quality control and healthcare data connectivity to support next-generation precision medicine workflows.
Beijing, China, July 15, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (Nasdaq: ITOC) (the "Company"), a technology-driven healthcare company focused on developing innovative digital medical solutions, today announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co., Ltd. ("Mili Medical"), a technology company focused on digital solutions for nuclear medicine and radiation treatment planning. The Company, through its indirect PRC subsidiary, has held a 60% equity interest in Mili Medical since its establishment.
The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities.
The Company is seeking to address the increasing focus on digital transformation, precision medicine and intelligent healthcare workflows by enabling hospitals and medical institutions to improve treatment efficiency, standardize clinical workflows and enhance patient care coordination.
Key Highlights
● Cloud-Based Transformation of Treatment Planning Software
Mili Medical is upgrading, with support from the Company, its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations.
● AI-Assisted Treatment Planning Under Development
The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review.
● Integrated Quality Control and Data Management
The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process.